Product Information
CLINDAMYCIN HCL 300 MG CAPSULE is a generic product labeled by AvPAK, priced at $0.1746 per EA under NDC 50268018515. Its NADAC has been published 295 times since Feb 10, 2021.
FDA first approved this application on Nov 5, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
AvPAKNDC
50268018515
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CLINDAMYCIN HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA207402FDA Approved
11/5/2018
TE Code
AB
On Market Since
10/27/2020
Pharmacological Classes
Price Statistics
The NADAC for CLINDAMYCIN HCL 300 MG CAPSULE has been published 295 times since Feb 10, 2021, and over the history we have for it it has declined 33.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1746 per EA |
|---|---|
| All-time high | $0.2913 (Jun 16, 2021) |
| All-time low | $0.1674 (Nov 20, 2024) |
| 52-week high | $0.1849 |
| 52-week low | $0.1680 |
| Median price | $0.2339 |
| Average price | $0.2245 |
| Largest weekly change | +33.6% (Aug 21, 2024) |
| Weeks tracked | 295 |
| Tracking since | Feb 10, 2021 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 4% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AvPAK manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Clindamycin hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Lincosamide Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CLINDAMYCIN HCL 300 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for CLINDAMYCIN HCL 300 MG CAPSULE, manufactured by AvPAK, is $0.1746 per EA (NDC 50268018515), effective Sep 30, 2026.
How has the price of CLINDAMYCIN HCL 300 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for CLINDAMYCIN HCL 300 MG CAPSULE has declined 33.8%. It has been tracked across 295 weekly CMS publications since Feb 10, 2021.
What are the highest and lowest recorded NADAC prices for CLINDAMYCIN HCL 300 MG CAPSULE?
Since Feb 10, 2021, the NADAC for CLINDAMYCIN HCL 300 MG CAPSULE has ranged from a low of $0.1674 (Nov 20, 2024) to a high of $0.2913 (Jun 16, 2021), with a median of $0.2339 per EA.
Are there cheaper alternatives to CLINDAMYCIN HCL 300 MG CAPSULE?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CLINDAMYCIN HCL 300 MG CAPSULE, is $0.1684 per EA — about 4% below CLINDAMYCIN HCL 300 MG CAPSULE.
Who manufactures CLINDAMYCIN HCL 300 MG CAPSULE?
CLINDAMYCIN HCL 300 MG CAPSULE (NDC 50268018515) is labeled by AvPAK, and CMS classifies it as a generic product.